It is demonstrated that rational construct design combined with systematic environmental screening reshapes the alpha-synuclein polymorphic landscape and promotes structural motifs characteristic of disease-associated fibrils.
Abstract
The structural diversity of alpha-synuclein amyloid fibrils is closely linked to the pathogenesis of Parkinson’s disease and related synucleinopathies. However, reproducing disease-associated fibril conformations from recombinant full-length protein in vitro has remained challenging. Inspired by successful truncation strategies developed for the Tau protein, we investigated whether removing the disordered terminal regions («fuzzy coat») of alpha-synuclein could bias fibril assembly toward disease-relevant folds. We designed a truncated construct comprising residues 31-100, corresponding to the structured core of patient-derived Parkinson’s disease fibrils, and systematically screened aggregation conditions across a broad range of pH values and ionic environments. Cryo-electron microscopy revealed four previously undescribed fibril structures, including new subtypes of the established type 1 and type 3 polymorphs and a novel fibril fold, termed type 10, which reproducibly formed under acidic conditions. Type 10 was observed as two distinct dimeric assemblies (10A and 10B) that share a common protofilament fold but differ in their inter-filament interfaces. Structural comparison with the patient-derived Parkinson’s disease polymorph revealed local similarities, including conserved β-strand organization and loop conformations within the fibril core, but remains structurally distinct overall. Our results demonstrate that rational construct design combined with systematic environmental screening reshapes the alpha-synuclein polymorphic landscape and promotes structural motifs characteristic of disease-associated fibrils.
It is established that low-twist filaments, which include over 75% of disease-associated Lewy aSyn amyloids, share a common structural core with high-twist forms and are the predominant aSyn species in samples that engage in templated infection.
Nicholas L. Yan, Mylan Mayer, Arthur A. Melo et al.· bioRxiv· 0 citations
It is shown that oligomerization drives a transition from dynamic monomers to increasingly ordered intermediates, relevant to models in which α-syn oligomerization alters normal membrane engagement during PD-associated aggregation.
Raya Sadighi, Andrea Istrati, Sigourney Karijodikoro et al.· ACS Central Science· 1 citation
Heterotypic interactions with Aβ42 reshape α-syn aggregation pathways and fibril conformations, generating structurally distinct α-syn fibril populations with different neuronal seeding activities, which provide a molecular framework for understanding how cross-talk between amyloidogenic proteins may contribute to stru...
Purnopama Saha, Teshani Liyanaarachchige, Anika Alim et al.· bioRxiv· 0 citations
A mechanistic model in which selectivity for aggregated aSyn arises from an emergent mesoscale interface combining a polyelectrolyte brush with recurrent core hotspots is presented, establishing full‐length, brain‐derived fibril ensembles as a practical framework for understanding ligand recognition at amyloid surfaces...
Carlos Pintado-Grima, Oriol Bárcenas, G. Tesei et al.· Protein Science· 0 citations
The misfolding of human islet amyloid polypeptide (hIAPP) into soluble oligomers is a primary pathological event in type 2 diabetes, with the early dimerization process representing a critical pharmacological target. Here, we investigate the molecular mechanism by which rosmarinic acid (RA) counteracts full-length hI...
Gang Wang, Xin-Qiu Zhu, Zi-Qian Zhao et al.· ACS Chemical Neuroscience· 0 citations
Non-fibrillar oligomeric forms of amyloid β (Aβ) mediate toxicity in Alzheimer’s disease (AD) with Aβ accumulation preceding tau aggregation and synaptic damage. Aβ oligomerization is thought to initiate from the smallest stable unit, the dimer, yet structural details of this species remain unclear due to its transient...
V. Streltsov, Yumi Irie, Y. Hanaki et al.· npj Dementia· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.